In this episode, we explore groundbreaking research revealing that lower doses of lurasidone (40-60mg) may be more effective for bipolar depression than higher doses. Could we be over-medicating our patients when the sweet spot for both efficacy and tolerability lies in this unexpected lower range?

Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.75 CMEs: Quick Take Vol. 74
• Lurasidone for Bipolar Depression: What Is the Optimal Dose?

In this episode, we explore a compelling comparison between olanzapine and risperidone for managing behavioral symptoms in dementia patients. Are the delusions we see in Alzheimer's disease actually true delusions, or something entirely different that requires a new treatment approach?

Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.75 CME: Quick Take Vol. 73
• Alzheimer’s Disease: Olanzapine vs. Risperidone for BPSD

In this episode, we explore the complex drug-drug interactions between psychedelics and psychiatric medications. Do SSRIs really blunt psychedelic effects, or is this just clinical folklore? We'll examine surprising new research and discuss potentially dangerous combinations every psychiatrist should know.

Faculty: Franklin King, M.D. Host: Richard Seeber, M.D.

• Learn more about our memberships here
• Earn 1.25 CME: Use of Psychedelic Drugs in Psychiatry
• Examining the Combined Use of Psychedelics and Psychiatric Drugs

In this episode, we challenge the conventional wisdom of “what gets them well keeps them well” by exploring groundbreaking Finnish research on bipolar disorder medication dosing. Does maintaining patients on high doses actually improve long-term outcomes, or could standard doses be the optimal strategy for relapse prevention?

Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D.

• Learn more about our memberships here
• Earn 0.75 CME: Quick Take Vol. 73
• Bipolar Disorder Maintenance: What’s the Optimal Dose Range?

In this episode, we explore how psychedelics like psilocybin disrupt the brain's default mode network, creating windows of neuroplasticity that correlate with mystical experiences and therapeutic breakthroughs in treatment-resistant depression, anxiety, and addiction.

Faculty: Franklin King, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 1.25 CMEs: Use of Psychedelic Drugs in Psychiatry
• How Psychedelics Influence Brain Networks

In this episode, we explore groundbreaking research showing how long-acting injectable antipsychotics can literally save lives in schizophrenia treatment. Could choosing the right medication delivery method be the difference between a patient thriving or facing premature death by 15-20 years?

Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.

• Learn more about our memberships here
• Earn 0.75 CME: Quick Take Vol. 73
• Long-Acting Injectables: Superior for Reducing Mortality in Schizophrenia?

In this episode, we explore the fascinating mechanisms behind psychedelic drugs in psychiatry, examining how substances like psilocybin and LSD work through 5-HT2A receptors to promote neuroplasticity. What if these compounds are hijacking an ancient stress response system designed to help us rapidly adapt to survive?

Faculty: Franklin King, M.D. Host: Richard Seeber, M.D.

• Learn more about our memberships here
• Earn 1.25 CME: Use of Psychedelic Drugs in Psychiatry
• The Mechanisms and Effects of Psychedelics

In this episode, we explore groundbreaking research comparing weight gain across eight common antidepressants. Using data from 183,000 patients, this study finally provides concrete numbers to answer the question patients ask most: How much weight will I gain on this medication?

Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.5 CME: Quick Take Vol. 72
• Which Antidepressants Cause the Most Weight Gain?

In this episode, we explore lisdexamfetamine as the first FDA-approved medication for binge eating disorder. Can one medication effectively treat both ADHD and binge eating simultaneously? We examine the evidence, duration of treatment, and strategies for addressing patient ambivalence in eating disorder pharmacotherapy.

Faculty: Scott Crow, M.D. Host: Richard Seeber, M.D.

• Learn more about our memberships here
• Earn 0.75 CME: Pharmacotherapy of Eating Disorders: An Update
• Binge Eating Disorder Pharmacotherapy: Lisdexamfetamine

In this episode, we explore groundbreaking Swedish research on GLP-1 receptor agonists as a potential new treatment for alcohol use disorder. Could diabetes medications like semaglutide revolutionize addiction treatment where traditional therapies have fallen short?

Faculty: David Gorelick, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.5 CME: Quick Take Vol. 72
• Which Antidepressants Cause the Most Weight Gain?